SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Cancer.

FTC May Intervene in Epic Systems Antitrust Lawsuit

What You Should Know: – During a visit to Wisconsin focused on corporate consolidation in the grocery industry, Federal Trade Commission (FTC) Chairwoman Lina Khan

October 4, 2024

Private equity firm offers $5.8 billion buyout of hospital billing company R1 RCM

R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private. Private equity

February 26, 2024

Fasting’s potential in fighting cognitive decline needs more human trials

Despite promising animal studies on fasting and caloric restrictions for neurodegenerative diseases, human clinical trials are scarce, underscoring the need for more research to validate

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.